Compound Radar

Globus Medical, Inc. (GMED) Stock Analysis

United States · Healthcare / Medical Devices

Price $75.04
Market cap $10.08B
Next earnings Nov 5, 2026
Entry status Good Entry

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

82
82/100 Elite Quality
  • Financial Health 70
  • Profitability 100
  • Business Quality 75
  • Balance Sheet 65
  • Cash Flow 80

Why this rating?

Health 82/100 — Elite Quality

Strongest Profitability 100/100
Softest Balance Sheet 65/100
Good Entry

A usable setup — not as clean as Strong Entry, but timing is not mixed or weak.

Company overview

Globus Medical, Inc. (GMED) is a Medical Devices company in the Healthcare sector. Compound Radar rates Globus Medical, Inc. 82/100 (Elite Quality) due to high business quality, steady revenue growth, and manageable leverage.

Investment profile

  • Quality High
  • Growth Moderate
  • Balance Sheet Adequate
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 19.19
  • Forward P/E 13.9
  • PEG 1.49
  • EV/Revenue 3.19

Profitability

  • Revenue Growth 5.9%
  • Gross Margin 69.0%
  • Operating Margin 24.8%
  • Net Margin 17.0%
  • ROE 11.8%

Financial strength

  • Cash $595.14M
  • Debt $111.91M
  • Net Cash $483.23M
  • Free Cash Flow $579.02M
  • Current Ratio 4.62

Similar companies

Peers in Medical Devices, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Devices →

FAQ

How Compound Radar scores and tracks Globus Medical, Inc. (GMED).

View Methodology & FAQ →